**Supplementary Table 1. Positive and negative statuses of sGFAP and sNfL levels using cut-off value at the individual time points of longitudinal analysis according to the clinical relapse and clinical relapse-free statuses (p < 0.001 by Fisher’s exact tests in both sGFAP and sNfL)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Clinical relapse status | Clinical relapse free status |  |
| Positive (sGFAP > 221.7 pg/ml) | 14 | 24 | 38 |
| Negative (sGFAP ≤ 221.7pg/ml) | 0 | 130 | 130 |
|  | 14 | 154 | 168 |
|  | Clinical relapse status | Clinical relapse free status |  |
| Positive (sNfL > 16.8 pg/ml) | 14 | 30 | 44 |
| Negative (sNfL ≤ 16.8 pg/ml) | 0 | 124 | 124 |
|  | 14 | 154 | 168 |

\*Abbreviations: sGFAP, serum glial fibrillary acidic protein, sNfL, serum neurofilament light chain

e-References

e1. Jakimovski D, Kuhle J, Ramanathan M, et al. Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. Ann Clin Transl Neurol 2019;6:1757-1770.